TeaserPublic and private partnerships are essential to foster innovation in health industries. Since the launch in 2009 of the first International R&D datings, a great number of companies committed themselves to develop private-public partnerships. Aligned with this main strategic objective, ARIIS in cooperation with the Institute of Cancer of Aviesan (the French national Alliance for life sciences and health) organizes the 8th International R&D Dating on Febuary 6th 2018 on the theme of “Immuno-oncology”.
Considered by the ASCO (American Society of Clinical Oncology) as “the clinical advance of year 2017”, the immuno-oncology has become part of the therapeutic arsenal used facing advanced cancers or recurrences. Yesterday on the prostate and the melanoma, these treatments are more and more effective against other cancers: lymphoma of Hodgkin, kidney, lung and even certain hematological cancers.
In this domain, the oldest sector of innovation concerns the targets of inhibition of control points, among which some are used in clinic. The mechanisms of signaling sent (CTLA-4 and PD-1/PD-L1, and more recently TIM3, GITR and LAG3) seem effective, even in the face of the hypermutability and the tumoral heterogeneousness. However, numerous questions remain : toxicity, stratification of patients, inhibitors' combination, addition of the other therapies, etc. That is why, at the same time, the innovations in the field of the immunomodulation are of a important interest: interleukine-2 (in particular IL-10, IL-15, IL-17 and IL-21) but also on interferons (in particular STING " stimulator of interferon genes "). The cellular immunotherapy emerges as a field of major interest, that it concerns lymphocytes reinjected with chimeric antigen receptor (CARs), or antibodies from tumoral cells. Finally, microbiota have also a significant interest because the immunogenic bacteria of the intestinal flora could become drug leads in oncology.
The 8th edition of the R&D Dating will cover, through selected presentations of top French experts, and face to face meeting, these aspects with the aim to facilitate and stimulate interactions between academic laboratories, networks of clinicians/biologists and industrial partners. The topics will include presentation of the predictive biomarkers of efficiency and side effect, the immunomodulatory and immunocellulary control points and therapeutic vaccines, rationalization of combinatorial therapeutic approaches, development and strengthening of preclinical models, new design of clinical trials with regard to the evolutions of standards of care, technological challenges in the control of the bioproduction related to advanced therapy medicinal products.